A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
Martin Sattler, Christoph Walz, Brian J. Crowley et al. · Blood · 2006
An activating mutation of the Jak2 tyrosine kinase (V617F) is commonly detected in polycythemia vera (65%-97%),[1][1]-[6][2] essential thrombocythemia (23%-57%),[1][1],[2][3],[4][4]-[6][2] and idiopathic myelofibrosis (35%-57%)[1][1],[2][3],[4][4]-[6][2] as well as at low percentages in other
Cited by 18 works. doi:10.1182/blood-2005-07-2899
Authors
- Martin Sattler
- Christoph Walz
- Brian J. Crowley
- Eva Lengfelder
- Pasi Antero Janne
- Andrew M. Rogers
- Yanan Kuang
- Robert J. Distel
- Andreas Reiter
- James D. Griffin
References
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
- A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
- The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes
- Identification of an Acquired JAK2 Mutation in Polycythemia Vera